Goldenwell Biotech, Inc.
GWLL
Rank in Stocks
#21993
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements... Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Hudson, Ohio.
Share Price
$0.6
Last synced: 2026-11-10
Market Cap
$59.40M
Change (1 day)
9.09%
Change (1 year)
-70.15%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Goldenwell Biotech, Inc. (GWLL)
Category
Healthcare
Operating Margin for Goldenwell Biotech, Inc. (GWLL)
Operating Margin as of November 2026 TTM: -409.10%
According to Goldenwell Biotech, Inc.'s latest financial reports, its current operating margin (TTM) is -409.10%. At the end of 2025 the company had an operating margin of -206,047.27%.
Operating Margin history for Goldenwell Biotech, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -409.10% | -99.80% |
| 2025 | -206,047.27% | 132.66% |
| 2024 | -88,559.71% | 1,672.79% |
| 2023 | -4,995.51% | 142.40% |
| 2022 | -2,060.89% | 178.24% |
| 2021 | -740.70% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 62.34% | -100.15% |
US
|
|
| 31.60% | -100.08% |
SE
|
|
| 30.13% | -100.07% |
FR
|
|
| 29.76% | -100.07% |
HK
|
|
| 30.46% | -100.07% |
IT
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Goldenwell Biotech, Inc.'s operating margin
What is Goldenwell Biotech, Inc.'s operating margin?
Goldenwell Biotech, Inc.'s operating margin is -409.10%, as of Nov 2026.
What was Goldenwell Biotech, Inc.'s operating margin in 2025?
In 2025, Goldenwell Biotech, Inc.'s operating margin was -206,047.27%, compared with -88,559.71% in 2024.
How has Goldenwell Biotech, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Goldenwell Biotech, Inc.'s operating margin was highest in 2020 (0.00%) and lowest in 2025 (-206,047.27%).
How does Goldenwell Biotech, Inc.'s operating margin compare with similar companies?
Goldenwell Biotech, Inc.'s operating margin (-409.10%) is lower than that of all 5 similar companies listed above. The highest among them is Royalty Pharma plc, with 62.34%.